Showing posts with label Ulcerative Colitis Market. Show all posts
Showing posts with label Ulcerative Colitis Market. Show all posts

Wednesday, 23 November 2016

EpiCast Report: Ulcerative Colitis Market Research Report - Epidemiology Popular Trends and Forecast to 2022

ResearchMoz added Latest Research Report titled " EpiCast Report: Ulcerative Colitis - Epidemiology Forecast to 2022 " to it's Large Report database.

Ulcerative colitis is a chronic inflammatory bowel disease (IBD) that causes ulcers in the innermost lining of the colon and rectum. The colons ability to absorb water is decreased, which leads to progressive loosening of the stool, bloody stool, and sometimes cramping or abdominal pain with urgency for bowel movement (CDC, 2013; NDDIC, 2013). The exact cause or triggers of the disease are yet to be identified. Globally, the incidence of ulcerative colitis varied from 0.34 cases per 100,000 population in China to as high as 15.1 cases per 100,000 population in the UK in the 1990s (Lok et al., 2008; Shivananda et al., 1996). The diagnosed prevalence of the condition ranged between 6.3 cases per 100,000 population in China in 2006 and 243 cases per 100,000 population in the UK during 20002002 (Lok et al., 2008; Rubin et al., 2000).

Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=181616

GlobalData epidemiologists forecast that there were 134,109 incident cases of ulcerative colitis in the 10MM in 2012, and the number of incident cases will grow 12.2% over the next decade to 150,530 incident cases. In 2012, there were 1,860,616 prevalent cases of ulcerative colitis in the 10MM. Each of the 10MM, except Germany, will see an increase in prevalent cases over the 10-year forecast period.

This forecast is supported by historical data for ulcerative colitis gathered from peer-reviewed journals and country-specific studies, in addition to reports taken from national health authorities and international organizations with interests in gastroenterology or inflammatory bowel disease (IBD). Another major strength of this analysis is that to take into account historical trends of ulcerative colitis and provide a robust forecast, GlobalData epidemiologists conducted linear regression analysis whenever sufficient historical data were available and the literature supported the resulting trend.

Read All Healthcare Market Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html

Table of Contents

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Reports 9

3 Epidemiology 10
3.1 Disease Background 10
3.2 Risk Factors and Comorbidities 11
3.2.1 Being Caucasian and Jewish can increase the risk of ulcerative colitis by almost 37 times 12
3.2.2 Family history of ulcerative colitis in first-degree relatives can increase the risk of ulcerative colitis almost three-fold 13
3.2.3 Current smokers have a lower chance of getting ulcerative colitis than former smokers or never smokers 13
3.3 Global Trends 15
3.3.1 US 16
3.3.2 5EU 19
3.3.3 Japan 22
3.3.4 Canada 24
3.3.5 China 26

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket
Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG

Monday, 14 November 2016

PharmaPoint: Ulcerative Colitis Market to grow at CAGR of 4.8% by 2022 - Global Drug Forecast and Market Analysis

ResearchMoz added Latest Research Report titled " PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 " to it's Large Report database.

During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada.

Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.

    Overall, major barriers to the growth of the UC market include 
    Remicade and Humira losing patent protection in the midforecast
    Austerity measures favoring generic prescribing
    Biosimilars are predicted to face low uptake due to the lack of regulatory guidelines in some markets, such as the US

Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=195531

In 2012, GlobalData estimates that the global UC market reached $4.2 billion across the 10 healthcare markets covered in our forecast: the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China, and India. By the end of the forecast period, in 2022, sales across these markets will grow steadily to reach $6.6 billion, representing a Compound Annual Growth Rate (CAGR) of 4.8% over the 10year timeframe.

Highlights

Key Questions Answered
  • How will the UC market (sales and patient numbers) evolve over the 10year forecast period from 2012 to 2022?
  • Which brands and specific drug classes did physicians select for their UC patients in 2012 and how do they foresee their prescribing behavior evolving over the next five years?
  • How will the launch of latestage pipeline therapies such as Entyvio and Kappaproct shape the future treatment landscape?
  • What are the remaining unmet needs and opportunities for drug developers within the UC market?
Read All Healthcare Market Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html

Table of Content

1 Table of Contents 10
1.1 List of Tables 17
1.2 List of Figures 23

2 Introduction 25
2.1 Catalyst 25
2.2 Related Reports 25
2.3 Upcoming Related Reports 25

3 Disease Overview 26
3.1 Etiology and Pathophysiology 26
3.1.1 Etiology 26
3.1.2 Pathophysiology 29
3.2 Symptoms 30
3.2.1 Quality of Life 31

4 Epidemiology 32
4.1 Disease Background 32
4.2 Risk Factors and Comorbidities 33
4.2.1 Being Caucasian and Jewish can increase the risk of UC by almost 37 times 34
4.2.2 A family history of UC in first-degree relatives can increase the risk of the disease by almost three-fold 34
4.2.3 Current smokers have a lower risk of developing UC than former smokers or never smokers 35

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket
Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG